Literature DB >> 33447372

Computational screening for potential drug candidates against the SARS-CoV-2 main protease.

Bruno Silva Andrade1, Preetam Ghosh2, Debmalya Barh3, Sandeep Tiwari4, Raner José Santana Silva5, Wagner Rodrigues de Assis Soares6, Tarcisio Silva Melo1, Andria Santos Freitas5, Patrícia González-Grande5, Lucas Sousa Palmeira1, Luiz Carlos Junior Alcantara4,7, Marta Giovanetti4,7, Aristóteles Góes-Neto8, Vasco Ariston de Carvalho Azevedo4.   

Abstract

Background: SARS-CoV-2 is the causal agent of the current coronavirus disease 2019 (COVID-19) pandemic. They are enveloped, positive-sense, single-stranded RNA viruses of the Coronaviridae family. Proteases of SARS-CoV-2 are necessary for viral replication, structural assembly, and pathogenicity. The approximately 33.8 kDa M pro protease of SARS-CoV-2 is a non-human homologue and is highly conserved among several coronaviruses, indicating that M pro could be a potential drug target for Coronaviruses.
Methods: Herein, we performed computational ligand screening of four pharmacophores (OEW, remdesivir, hydroxychloroquine and N3) that are presumed to have positive effects against SARS-CoV-2 M pro protease (6LU7), and also screened 50,000 natural compounds from the ZINC Database dataset against this protease target.
Results: We found 40 pharmacophore-like structures of natural compounds from diverse chemical classes that exhibited better affinity of docking as compared to the known ligands. The 11 best selected ligands, namely ZINC1845382, ZINC1875405, ZINC2092396, ZINC2104424, ZINC44018332, ZINC2101723, ZINC2094526, ZINC2094304, ZINC2104482, ZINC3984030, and ZINC1531664, are mainly classified as beta-carboline, alkaloids, and polyflavonoids, and all displayed interactions with dyad CYS145 and HIS41 from the protease pocket in a similar way as other known ligands. Conclusions: Our results suggest that these 11 molecules could be effective against SARS-CoV-2 protease and may be subsequently tested in vitro and in vivo to develop novel drugs against this virus. Copyright:
© 2020 Silva Andrade B et al.

Entities:  

Keywords:  SARS-CoV-2; inhibitors; natural compounds; pharmacophore; protease; virtual screening

Year:  2020        PMID: 33447372      PMCID: PMC7780344.2          DOI: 10.12688/f1000research.23829.2

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  4 in total

Review 1.  Natural therapeutics against SARS CoV2: the potentiality and challenges.

Authors:  Anirban Bhar; Akansha Jain; Sampa Das
Journal:  Vegetos       Date:  2022-06-15

2.  Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease.

Authors:  Marisa G Santibáñez-Morán; Edgar López-López; Fernando D Prieto-Martínez; Norberto Sánchez-Cruz; José L Medina-Franco
Journal:  RSC Adv       Date:  2020-07-01       Impact factor: 4.036

3.  Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2.

Authors:  Shafi Mahmud; Gobindo Kumar Paul; Suvro Biswas; Shamima Afrose; Mohasana Akter Mita; Md Robiul Hasan; Mst Sharmin Sultana Shimu; Alomgir Hossain; Maria Meha Promi; Fahmida Khan Ema; Kumarappan Chidambaram; Balakumar Chandrasekaran; Ali M Alqahtani; Talha Bin Emran; Md Abu Saleh
Journal:  Front Mol Biosci       Date:  2021-05-10

Review 4.  Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to.

Authors:  Probir Kumar Ojha; Supratik Kar; Jillella Gopala Krishna; Kunal Roy; Jerzy Leszczynski
Journal:  Mol Divers       Date:  2020-09-02       Impact factor: 2.943

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.